Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series.
作者信息
Sawada Tsunaki, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Ishikawa Eri, Murate Kentaro, Kawashima Hiroki
机构信息
Department of Endoscopy, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan.
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan.
出版信息
Inflamm Bowel Dis. 2025 Jul 7;31(7):2040-2041. doi: 10.1093/ibd/izaf018.
Abstract
摘要
相似文献
1
Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series.先前使用过优特克单抗的患者使用古塞奇尤单抗的疗效：病例系列
Inflamm Bowel Dis. 2025 Jul 7;31(7):2040-2041. doi: 10.1093/ibd/izaf018.
2
Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis.比较米利珠单抗与目前已批准用于溃疡性结肠炎治疗的生物药物的疗效和安全性：系统评价和网络荟萃分析。
Pharmacotherapy. 2024 Oct;44(10):811-821. doi: 10.1002/phar.4611. Epub 2024 Sep 25.
3
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.溃疡性结肠炎连续治疗152周后mirikizumab的三年疗效和安全性：LUCENT-3开放标签扩展研究结果
Inflamm Bowel Dis. 2024 Oct 25. doi: 10.1093/ibd/izae253.
4
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center.mirikizumab治疗溃疡性结肠炎：来自大型三级中心人群的初始真实世界数据
Dig Dis Sci. 2025 May;70(5):1864-1872. doi: 10.1007/s10620-025-08950-y. Epub 2025 Mar 6.
5
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
6
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎的缓解。
Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4.
9
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3.
10
Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.他克莫司（FK506）治疗皮质激素抵抗性溃疡性结肠炎的诱导缓解。
Cochrane Database Syst Rev. 2022 Apr 7;4(4):CD007216. doi: 10.1002/14651858.CD007216.pub2.
引用本文的文献
1
Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis.白细胞介素23：溃疡性结肠炎的发病机制参与及治疗靶点
J Clin Med. 2025 Jun 28;14(13):4590. doi: 10.3390/jcm14134590.
本文引用的文献
1
Are all the IL-23 blockers the same in inflammatory bowel disease?在炎症性肠病中，所有的白细胞介素-23阻滞剂都一样吗？
Nat Rev Gastroenterol Hepatol. 2024 Mar;21(3):138-139. doi: 10.1038/s41575-023-00889-7.
2
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.美沙拉嗪诱导和维持治疗溃疡性结肠炎的疗效。
N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940.
3
IL-23: one cytokine in control of autoimmunity.IL-23：控制自身免疫的一种细胞因子。
Eur J Immunol. 2012 Sep;42(9):2263-73. doi: 10.1002/eji.201242598.
Zotero 插件